Last updated: 2026-09-16 09:05:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Viridian Therapeutics, Inc. (VRDN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $21,75, with a market capitalisation of $2,52B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $13,18 to $34,29. This page covers its latest market performance, valuation, price trends and company information.
$2,52B | |
$21,73 | |
$39,00 | |
$9,47 | |
$21,83 | |
142,00 | |
1,89M | |
-- | |
$34,29 | |
$13,18 | |
-- | |
-- |
Viridian Therapeutics, Inc. (VRDN) is trading at $21,75 in pre-market trading as of 2026-09-16 08:56:00, down 0,37% ($0,08) from the previous close of $21,83
Pre-market trading shows how investors are pricing VRDN before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Viridian Therapeutics, Inc. (VRDN) moved from $22,92 to $21,75, representing a decline of 5,11% ($1,17).
The stock traded between $21,19 and $23,84 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1,28 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 40,6%
VRDN is currently trading at $21,75, placing it 40,6% of the way from its 52-week low of $13,18 to its 52-week high of $34,29. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 252 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Viridian Therapeutics, Inc. (VRDN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.